Variation in furanocoumarin content and new furanocoumarin dimers in commercial grapefruit (Citrus paradisi Macf.) juices

Journal of Food Science

Volumn 70, Issue 4, 2005, Pages

  Widmer, Wilbur ^a   Haun, Carl ^b  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b Florida Department of Citrus   (United States)

Author keywords

Citrus paradisi; Coumarin; CYP3A4; Drug interaction; Furanocoumarin; Grapefruit; P450; Psoralen

Indexed keywords

CITRUS X PARADISI;

EID: 19444378434     PISSN: 00221147     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2621.2005.tb07178.x     Document Type: Article

References (24)

1. Ameer B, Weintraub RA. 1997. Drug interactions with grapefruit juice. Clin Pharmacokinet 33:103-21.
2. Bailey DG, Arnold JM, Munoz C, Spence JD. 1993. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 53:637-42.
3. Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD. 1993. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 53:589-94.
4. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR. 1998. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′- dihydroxybergamottin in humans. Clin Pharmacol Ther 64:248-56.
5. Bailey DG, Munoz C, Arnold JM, Strong HA, Spence JD. 1992. Grapefruit juice and naringin interaction with nitrendipine. Clin Pharmacol Ther 51:156.
6. Bailey DG, Spence JD, Edgar B, Baycliff CD, Arnold JM. 1989. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 12:357-62.
7. Dahan A, Altman H. 2004. Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur J Clin Nutrit 58:1-9.
8. Dresser GK, Spence JD, Bailey DG, 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P4503A4 inhibition. Clin Pharmacokinet 38:41-57.
9. Edwards DJ, Bellevue FH, Woster PM. 1996. Identification of 6′7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 24:1287-90.
10. Edwards DJ, Bernier SM. 1996. Naringin and naringenin are not the primary CYP3A4 inhibitiors in grapefruit juice. Life Sci 59:1025-30.
11. Fuhr U, Klittich K, Staib AH. 1993. Inhibitory effect of grapefruit juice and the active component naringinen on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 35:431-6.
12. Fuhr U, Kummert AL. 1995. The fate of naringin in humans: a key to grapefruit juice-drug interactions? Clin Pharmacol Ther 58:365-73.
13. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. 1997. Specific CYP3A4 inhibitiors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 5:391-6.
14. Greenblatt DJ, Patki KC, Von Moltke LL, Shader RL. 2001. Drug interactions with grapefruit juice: an update. Clin Psychopharm 21:357-9.
15. Guo LQ, Fukuda K, Ohta T, Yamazoe Y. 2000. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28:766-71.
16. Harris J, inventor; Bioavailability Systems, LLC, assignee. 1998. Method for the preparation of a first-pass effective citrus-derived substance and product thereof. U.S. patent 5,820,915. Issued Oct 13, 1998.
17. Harris J, inventor; Bioavailability Systems, LLC, assignee. 1999. Safe citrus juice and process for preparation. U.S. patent 5,993,887. Issued Nov 30, 1999.
18. Harris J, inventor; Bioavailability Systems, LLC, assignee. 2001. Anti-first-pass effect compounds and citrus extract. U.S. patent 6,255,337. Issued July 3, 2001.
19. Harris J, inventor; Bioavailability Systems, LLC, assignee. 2002. Anti-first-pass effect compounds. U.S. patent 6,476,066. Issued Nov 5, 2002.
20. Harris J, inventor; Bioavailability Systems, LLC, assignee. 2003. Anti-first-pass effect compounds. U.S. patent 6,666,766. Issued Dec 9, 2003.
21. Huang SM, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD. 2004. Drug interactions with herbal products and grapefruit juice: a conference report. Clin PharmTher 75:1-12.
22. Kane GC, Lipsky JJ. 2000. Drug-grapefruit juice interactions. Mayo Clin Proc 75:933-42.
23. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. 2000. Inhibition selectivity of grapefruit juice components on human cytochrome P450. Arch Biochem Bio-Physics 378:356-63.
24. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE. 2003. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharm 43:831-9.